ClinicalTrials.gg
RecruitingNCT07751159Updated Nov 16, 2026

Radiation Therapy Approaches for People With Prostate Cancer

A Phase 2 interventional study of Standard of Care HDR Brachytherapy and SBRT in Prostate Cancer Patients, Non-metastatic Prostate Cancer and High Risk Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 16, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center — 15 open to participants now, 41 under way, 4 of them phase 3. Prostatic Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
26th of 99
126 · median 51
Started
2026
with 5 others
Phase 2
40 of 138
4 open now
Primary completion
2030-07
later than 40 of 40 live
Registered
138th of 138
by date

Among the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 26th largest by planned enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2026, is one of 40 in phase 2, reaches primary completion later than 40 of the 40 other live ones, and was the 138th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.

03

Conditions studied

  • Prostate Cancer Patients
  • Non-metastatic Prostate Cancer
  • High Risk Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • Non-metastatic prostate cancer
  • intermediate prostate cancer
  • high risk prostate cancer
  • very high risk prostate cancer
  • Memorial Sloan Kettering Cancer Center
  • 26-288
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non- prostate cancer.
  • Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed)
  • Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT

Exclusion criteria

Exclusion Criteria:

  • None

Clinical Considerations for Treatment Eligibility

Although not formal exclusion criteria for study participation, certain clinical factors may influence the treating physician's assessment of suitability for HDR brachytherapy boost or SBRT. Patients who are typically considered less suitable candidates for these approaches in routine clinical practice may include those with:

  • Pre-ADT prostate volume >90 cc (measured by MRI or other imaging)
  • Severe baseline urinary symptoms (IPSS >20) to standard medical management
  • Active prostatitis
  • Prior pelvic radiation therapy
  • Active inflammatory bowel disease
  • Inability to safely undergo anesthesia Final determination of treatment suitability will be made by the treating physician based on clinical judgment and standard institutional practice.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    Arm A: HDR Brachytherapy Boost + SBRT

    Standard of Care Brachytherapy/Radiation and SBRT

    Radiation: Standard of Care HDR Brachytherapy · Radiation: SBRT

  • Experimental
    Arm B: SBRT Alone

    SBRT alone

    Radiation: SBRT

Interventions

  • RadiationStandard of Care HDR Brachytherapy

    HDR Brachytherapy

  • RadiationSBRT

    SBRT alone

06

What researchers measure

Primary outcomes

  1. Change in International Prostate Symptom Score / IPSS at 3 months

    Change in International Prostate Symptom Score / IPSS to measure if SBRT alone results in less acute patient reported urinary symptoms measured by IPSS at 3 months than HDR brachytherapy boost combined with SBRT

    Time frame: 3 months

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
  • Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
    New York, New York 10065, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
  • Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Daniel Gorovets, MD · Contact212-639-3983
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2030, 48 months after the start.

Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's planned 48 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 7, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Jul 31, 2030
CompletionEst.
Jul 31, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
8 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • AddedClinical Considerations for Treatment Eligibility
  • AddedAlthough not formal exclusion criteria for study participation, certain clinical factors may influence the treating physician's assessment of suitability for HDR brachytherapy boost or SBRT. Patients who are typically considered less suitable candidates for these approaches in routine clinical practice may include those with:
  • AddedPre-ADT prostate volume >90 cc (measured by MRI or other imaging)
  • AddedSevere baseline urinary symptoms (IPSS >20) refractory to standard medical management
  • AddedActive prostatitis
  • AddedPrior pelvic radiation therapy
  • AddedActive inflammatory bowel disease
  • AddedInability to safely undergo anesthesia Final determination of treatment suitability will be made by the treating physician based on clinical judgment and standard institutional practice.
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Eligibility 8 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • AddedClinical Considerations for Treatment Eligibility
    • AddedAlthough not formal exclusion criteria for study participation, certain clinical factors may influence the treating physician's assessment of suitability for HDR brachytherapy boost or SBRT. Patients who are typically considered less suitable candidates for these approaches in routine clinical practice may include those with:
    • AddedPre-ADT prostate volume >90 cc (measured by MRI or other imaging)
    • AddedSevere baseline urinary symptoms (IPSS >20) refractory to standard medical management
    • AddedActive prostatitis
    • AddedPrior pelvic radiation therapy
    • AddedActive inflammatory bowel disease
    • AddedInability to safely undergo anesthesia Final determination of treatment suitability will be made by the treating physician based on clinical judgment and standard institutional practice.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07751159
Collaborators
Palette Life Sciences, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Jul 31, 2026
Primary completion
Jul 31, 2030 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Daniel Gorovets, MD
Contact
gorovetd@mskcc.org
212-639-3983
Himanshu Nagar, MD
Contact
nagarh1@mskcc.org
212-639-6478
Daniel Gorovets, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion